Atrium Health Levine Cancer Institute | Strategic Alliance Partners

Latest from Atrium Health Levine Cancer Institute

Coleman and Brown Review Advancing Applications for PARP Inhibition in Ovarian Cancer

March 25, 2021

Dr. Coleman and Dr. Brown discuss how understandings of BRCA and patient eligibility for PARP inhibitors have evolved in ovarian cancer, the effects of frontline maintenance trials on treatment recommendations, the clinical significance of the findings from the ARIEL4 trial, and where PARP inhibition is headed in the field.